- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- April 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- November 2023
- 181 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- June 2022
- 140 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- November 2022
- 111 Pages
Middle East, Africa
From €1365EUR$1,500USD£1,170GBP
- Report
- February 2021
- 56 Pages
Global
€1200EUR$1,318USD£1,028GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
Adderall is a psychostimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. Adderall is one of the most commonly prescribed medications for ADHD, and is also used off-label for other mental disorders such as depression and anxiety.
Adderall is available in both immediate-release and extended-release forms, and is typically taken orally. It is available in generic form, as well as under the brand names Adderall XR and Mydayis. Common side effects of Adderall include insomnia, dry mouth, loss of appetite, and weight loss.
The Adderall market is a large and growing one, with many companies competing for a share of the market. Some of the major players in the Adderall market include Shire Pharmaceuticals, Teva Pharmaceuticals, Actavis, and Mylan. Other companies such as Impax Laboratories, CorePharma, and Mallinckrodt Pharmaceuticals also produce generic versions of Adderall. Show Less Read more